Protein-bound paclitaxel explained
| Verifiedfields: | changed |
| Verifiedrevid: | 443693471 |
| Type: | combo |
| Component1: | Paclitaxel |
| Class1: | Mitotic inhibitor |
| Component2: | Albumin |
| Class2: | Delivery vehicle |
| Tradename: | Abraxane, others |
| Dailymedid: | Paclitaxel |
| Pregnancy Au: | D |
| Routes Of Administration: | Intravenous |
| Atc Prefix: | L01 |
| Atc Suffix: | CD01 |
| Legal Au: | S4 |
| Legal Ca: | Rx-only |
| Legal Ca Comment: | [1] |
| Legal Uk: | POM |
| Legal Us: | Rx-only |
| Legal Eu: | Rx-only |
| Legal Status: | Rx-only |
| Chemspiderid: | none |
| Cas Number: | 33069-62-4 |
| Unii: | P88XT4IS4D |
| Drugbank: | DB01229 |
| Kegg: | D00491 |
Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division.[2] [3] In this formulation, paclitaxel is bonded to albumin as a delivery vehicle.[4] It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".[5]
This treatment was approved in the United States in 2005,[6] and the European Union in 2008, for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed.[7] [8] In 2012, the FDA widened the approved uses to include treatment for NSCLC.[9] [10] In 2013, the FDA approved protein-bound paclitaxel for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX.[11]
Society and culture
Abraxane is registered on the Australian Register of Therapeutic Goods for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.[12] Abraxane is also included on the Schedule of the Australian Pharmaceutical Benefits Scheme although[13] the manufacturer was unable to convince the independent Pharmaceutical Benefits Advisory Committee that the drug warranted a higher price than existing comparator drugs.[14] Protein-bound paclitaxel was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform.[15]
In 2010, Abraxis was acquired by Celgene, which now markets Abraxane.[16] Total revenue from the sales of Abraxane for 2009 were $314.5 million.[17] In 2013, Abraxane was FDA approved for the treatment of pancreatic cancer.[18] In 2014, Abraxane's sales were $848 million, 31 percent year-over-year increase.[19] In 2019 Bristol Meyers Squibb acquired Celgene for $74 billion dollars, and thus acquired Abraxis Bioscience and the rights to manufacture and market Abraxane.[20]
The UK's National Institute for Health and Care Excellence (NICE) announced in 2015, that it would not support the routine use of protein-bound paclitaxel in advanced pancreatic cancer on the NHS.[21] However, this decision was changed in September 2017.[22] It has continued to be reimbursed in England since then, despite questionable real world effectiveness.[23]
Further reading
- Miele E, Spinelli GP, Miele E, Tomao F, Tomao S . Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer . International Journal of Nanomedicine . 4 . 99–105 . 2009 . 19516888 . 2720743 . 10.2147/ijn.s3061 . free .
- Stinchcombe TE . Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel . Nanomedicine . 2 . 4 . 415–423 . August 2007 . 17716129 . 10.2217/17435889.2.4.415 .
- Gradishar WJ . Albumin-bound paclitaxel: a next-generation taxane . Expert Opinion on Pharmacotherapy . 7 . 8 . 1041–1053 . June 2006 . 16722814 . 10.1517/14656566.7.8.1041 . 12736839 .
Notes and References
- Web site: Product monograph brand safety updates . . 7 July 2016 . 3 April 2024.
- Web site: Definition of "protein-bound paclitaxel" . National Cancer Institute Dictionary of Cancer Terms . 2011-02-02. mdy-all .
- Web site: Nab-paclitaxel (Abraxane) . 2025-04-13 . www.cancerresearchuk.org . en.
- Web site: Paclitaxel Albumin-stabilized Nanoparticle Formulation . National Cancer Institute Drug Information . 2006 .
- Web site: Abraxane. Orpha Net . September 6, 2013 . July 20, 2015 .
- Knapp A . August 27, 2020. The Inside Story Of Biotech's Barnum And His Covid Cures. 2020-08-27. Forbes. en.
- Web site: FDA Approval for Nanoparticle Paclitaxel . National Cancer Institute Drug Information . 2006 . 18 February 2008 . 24 July 2008 . https://web.archive.org/web/20080724085354/http://www.cancer.gov/cancertopics/druginfo/fda-nanoparticle-paclitaxel . dead .
- Web site: Abraxane EPAR . European Medicines Agency (EMA) . 9 March 2020 . 9 March 2020.
- News: FDA approves Celgene's Abraxane for lung cancer . mdy-all . Reuters . 2012-10-12 .
- Web site: Paclitaxel (Abraxane). https://web.archive.org/web/20121014154607/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm. dead. 14 October 2012. U.S. Food and Drug Administration. October 11, 2012. 10 December 2012.
- News: Pollack A . F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer . . September 7, 2013 . September 6, 2013.
- Web site: Resolution 9190. Therapeutic Goods Administration (Tga). June 6, 2008.
- Vines T, Faunce T . Assessing the safety and cost-effectiveness of early nanodrugs . Journal of Law and Medicine . 16 . 5 . 822–845 . May 2009 . 19554862 .
- Web site: PBAC, Public Summary Document. November 2008. health.gov.au.
- Web site: Celgene: A Global Biopharmaceutical Company Committed to Improving the Lives of Patients Worldwide with Innovative and Life-Changing Treatments. www.abraxisbio.com.
- Celgene Completes Acquisition of Abraxis. Celgene.
- Web site: Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC . 2010. www.genengnews.com/ .
- FDA. FDA approves Abraxane for late-stage pancreatic cancer. https://web.archive.org/web/20130909082039/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367442.htm. dead. 9 September 2013.
- Celgene. Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results (NASDAQ:CELG).
- Web site: Kansteiner . Fraiser . Bristol Myers' subsidiary behind cancer blockbuster Abraxane slapped with FDA warning letter . Fierce Pharma . 2022-11-09 . 2025-03-12.
- Web site: NHS England stop access to Abraxane - Pancreatic Cancer UK. September 2015. www.pancreaticcancer.org.uk/. 24 December 2015. 25 December 2015. https://web.archive.org/web/20151225115559/http://www.pancreaticcancer.org.uk/latest-news/2015/september/last-hope-dashed-for-access-to-life-extending-pancreatic-cancer-drug-on-the-nhs-in-england/#sthash.PpHk2Lur.dpuf. dead.
- Web site: 2017-09-06 . Overview Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer Guidance NICE . 2024-12-26 . www.nice.org.uk.
- Wadd N, Peedell C, Polwart C . Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England . Clinical Oncology . 34 . 8 . 497–507 . August 2022 . 35584974 . 10.1016/j.clon.2022.04.012 .